SPIN2B: Key Regulator of Sodium-Glucose Cotransporter and Potential Drug Target

Target Name: SPIN2B

NCBI ID: G474343

SPIN2B

SPIN2B: Key Regulator of Sodium-Glucose Cotransporter and Potential Drug Target

SPIN2B (TDRD26) is a protein that is expressed in various tissues throughout the body, including the brain, heart, liver, and kidneys. It is a key regulator of the sodium-glucose cotransporter (SGLT), a protein that is responsible for reabsorbing glucose from the gut into the bloodstream.

SPIN2B is a 26-kDa protein that is composed of 218 amino acid residues. It has a molecular weight of 29,117 Da and a calculated pI of 1.5. SPIN2B is expressed in a variety of tissues, including the brain, heart, liver, and kidneys. It is highly expressed in the brain, where it is the most abundant protein in the brain.

SPIN2B is a key regulator of the sodium-glucose cotransporter (SGLT), a protein that is responsible for reabsorbing glucose from the gut into the bloodstream. The SGLT is expressed in the brain and has been implicated in a number of neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia.

SPIN2B is involved in the regulation of a variety of cellular processes, including cell signaling, cell adhesion, and neurotransmitter release. It is a member of the T-cell receptor (TCR) signaling pathway, which is involved in the regulation of T-cell development, function, and survival.

SPIN2B has also been shown to play a role in the regulation of inflammation. It is a target for several pro-inflammatory cytokines, including TNF-alpha, IL-18, and IL-6. These cytokines are involved in the regulation of immune cell function, and their production is often enhanced in response to an infection or injury.

SPIN2B is also a potential drug target for several diseases. Its expression has been implicated in a number of neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. It is also involved in the regulation of T-cell development and function, which is important for the regulation of immune cell function. These factors make SPIN2B an attractive target for the development of new treatments for a variety of neurological and psychiatric disorders.

In conclusion, SPIN2B is a protein that is expressed in various tissues throughout the body and is involved in the regulation of a variety of cellular processes, including cell signaling, cell adhesion, and neurotransmitter release. It is a key regulator of the sodium-glucose cotransporter and has been shown to play a role in the regulation of inflammation. Its expression has been implicated in a number of neurological and psychiatric disorders, making it an attractive target for the development of new treatments for these disorders. Further research is needed to fully understand the role of SPIN2B in the regulation of cellular processes and its potential as a drug target.

Protein Name: Spindlin Family Member 2B

Functions: Involved in the regulation of cell cycle progression, this activity is related to the inhibition of apoptosis following the removal of essential growth factors (PubMed:12145692). Exhibits H3K4me3-binding activity (PubMed:29061846)

The "SPIN2B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SPIN2B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets